Previous 10 | Next 10 |
DUBLIN, Ireland and BRIDGEWATER, N.J., April 19, 2022 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with members of Amarin’s senior management team to discuss the Company's first quarter 2022 financial results on Wednesda...
DUBLIN, Ireland and BRIDGEWATER, N.J., April 01, 2022 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced in vitro research results suggesting that Eicosapentaenoic Acid (EPA), in combination with widely prescribed statins (often referred to under brand names LIPITO...
Gainers: Lulu's Fashion Lounge Holdings (LVLU) +12%. Chicken Soup for the Soul Entertainment (CSSE) +8%. American Outdoor Brands (AOUT) +7%. Immuneering Corporation (IMRX) +6%. Service Properties Trust (SVC) +5%. Losers: Spero Therapeutics (SPRO) -24%. Duck Creek Tech...
Baker Brothers’ 13F portfolio value decreased from $22.77B to $20.55B this quarter. Incyte and Legend Biotech stakes were increased this quarter. The top three positions are Seagen, BeiGene, and Incyte Corporation and they add up to almost ~63% of the portfolio. For f...
Amarin Corporation (NASDAQ:AMRN), a commercial-stage biotech focused on cardiovascular diseases, announced on Monday that the Swedish Dental and Pharmaceutical Benefits Agency (TLV) approved its heart disease therapy Vazkepa for national reimbursement. The decision marks the first national re...
Marks First Health Technology Assessment (HTA) Reimbursement in Europe and Initiation of Next Phase of the Company’s Growth Strategy Company Provides Progress Update on European and International Expansion Plans DUBLIN, Ireland and BRIDGEWATER, N.J., March 28, 2022 ...
DUBLIN, Ireland and BRIDGEWATER, N.J., March 21, 2022 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced a diverse and full slate of supported and/or funded research on VASCEPA ® /VAZKEPA (icosapent ethyl) to be presented in six posters at the American College...
Amarin Corporation (AMRN +1.2%), the maker of lipid-lowering agent Vascepa, recovered from three back-to-back days of losses after Piper Sandler issued positive remarks on the company’s sales strategy in Europe. The company’s lead product Vascepa, branded as Vazkepa in Europe, i...
A new analysis from Amarin (NASDAQ:AMRN) found that Vascepa (icosapent ethyl) significantly lowered the risk of potentially fatal cardiovascular events in patients who have received a percutaneous coronary intervention ("PCI"). The analysis is from data from the REDUCE-IT study. In pati...
A new post hoc sub-analysis of the landmark REDUCE-IT Study, published in the Journal of the American Heart Association (JAHA), found VASCEPA ® significantly reduced the risk of cardiovascular death, strokes, heart attacks, coronary revascularization, and unstable angina by 34% i...
News, Short Squeeze, Breakout and More Instantly...
Amarin Corporation plc Company Name:
AMRN Stock Symbol:
NASDAQ Market:
Amarin Corporation plc Website:
-- Portuguese Ministry of Health approves VAZKEPA® (icosapent ethyl) for national reimbursement to reduce the risk of cardiovascular (CV) events in patients with established cardiovascular disease (CVD) 1 -- -- Approval marks eighth national reimbursement of VAZKEPA®...
DUBLIN and BRIDGEWATER, N.J., July 17, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with Aaron Berg, President & CEO, and members of Amarin’s senior management team to discuss its second quarter 2024 results followed ...
-- VASCEPA Approved by the National Medical Products Administration (NMPA) To Reduce the Risk of Cardiovascular Events as an Adjunct to Statin Therapy in Adult Patients with Elevated Triglyceride (TG) Levels (≥150 mg/dL) and Other High-Risk Characteristics as Studied in REDUCE-IT -- ...